CSL Seqirus Korsuva (difelikefalin) is now accessible via the PBS for adults experiencing moderate-to-severe pruritus associated with chronic kidney disease (CKD).
Korsuva aims to alleviate the intense itching that particularly affects haemodialysis patients.
CSL stated the itching is related to CKD, a condition where normal kidney function declines, often impacting quality of life, including sleep disturbances, depression, and poorer overall health.
Studies suggest over two-thirds of haemodialysis patients endure this discomfort, with significant implications for their treatment compliance and survival rates.
With over 12,000 Australians living with CKD currently undergoing haemodialysis, the burden of associated conditions remains high.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 May 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 May 24
